Design of a potential colonic drug delivery system of mesalamine

Pharmaceutical Development and Technology

Volumn 13, Issue 5, 2008, Pages 447-456

  Gohel, Mukesh C ^a   Parikh, Rajesh K ^a   Nagori, Stavan A ^a   Dabhi, Mahesh R ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

Coating; Colonic drug delivery system; Hydroxypropyl methylcellulose and Eudragit S100; Mesalamine

Indexed keywords

CALITOFALK; EUDRAGIT; MESALAZINE; MESAZAL; UNCLASSIFIED DRUG;

ARTICLE; COLON; DELAYED DRUG RELEASE; DRUG COATING; DRUG DELIVERY SYSTEM; PH; PRIORITY JOURNAL; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; TABLET SURFACE; TABLET THICKNESS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; COLON; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; MESALAMINE; METHYLCELLULOSE; POLYMETHACRYLIC ACIDS; SOLUBILITY; TABLETS; TIME FACTORS;

EID: 51949111446     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802088679     Document Type: Article

References (48)

1. Saffarin M, Kumar GS, Savariar C, Burnham CJ, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;233(4768):1081-1084.
2. Ashord M, Fell JT, Attwood D, Woodhead PJ. An in vitro investigation into the suitability of pH dependent polymers for colon targeting. Int J Pharm. 1993;91(2-3):241-245.
3. Gupta VK, Beckert TE, Price JC A novel pH and time based multi unit potential colonic drug delivery system I development. Int J Pharm. 2001;213(1-2):83-91.
4. In: Vyas, S.P.; Khar, R.K., ed. Controlled Drug Delivery-Concepts and Advances; Vallabh Prakashan: New Delhi, 2002; 218-256.
5. Pozzi F, Furlani P, Gazzaniga A, Davis SS, Wilding IR. The time-clock system: a new oral dosage form for fast and complete release of drug after predetermined lag time. J Control Release. 1994;31(1):99-108.
6. Steed KP, Hooper G, Monti N, Benedetti S, Fornasini G, Wilding IR. The use of pharacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("time clock" system). J Control Release. 1997;49(2-3):115-122.
7. Khan MZI, Prebeg Z, Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers, I: manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J Control Release. 1999;58(2):215-222.
8. Krishnaiah YSR, Satyanarayan S, Rama Prasad YU. Studies of guar gum compression coated 5-aminosalicylic acid tablets for colon specific drug delivery. Drug Dev Ind Pharm. 1999;25(5):651-657.
9. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci. 2000;10(1):53-52.
10. Leopold CS, Eikeler D. Basic coating polymers for the colon-specific drug delivery in inflammatory bowel disease. Drug Dev Ind Pharm. 2000;26(12):1239-1246.
11. Raghavan CV, Muthulingam C, Jeneta JAJ, Thengungal KR. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem Pharm Bull. 2002;50(7):892-895.
12. Vandamne ThF, Lenourry A, Charrueau C, Chameil JC. The use of polysaccharides to target drugs to the colon. Carbohydrate Polymers. 2002;48(3): 219-231.
13. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003;6(1):33-66.
14. Liu L, Fishman L, Kost J, Hicks KB. Pectin based systems for colon specific drug delivery via oral route. Biomaterials. 2003;24(19):3333- 3343.
15. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev. 2005;57(2):247-265.
16. Rai G, Jain SK, Agrawal S, Bhadra S, Pancholi SS, Agrawal GP. Chitosan hydrochloride based microspheres of albendazole for colonic drug delivery. Pharmazie. 2005; 60(2):131-134.
17. Lerner EI, Flashner M, Penhasi A, Gastointestinal drug delivery system. US patent 5,840,332. 1998.
18. Schroder H., Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972;13(4):539-551.
19. Healey JN. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. J Gastroenterol Suppl. 1990;172:47-51.
20. Yang L, Chu JS, Fix JA.Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm. 2002;235(1-2):1-15.
21. Basit A, Bloor J. Perspectives on colonic drug delivery. Business Briefing: PharmaTech. 2003:185-190.
22. Singh BN, Kim KH. Drug delivery-oral route. In: Encyclopedia of pharmaceutical Technology. Swarbrick J., Boylan J. C., eds., Marcel Dekker: New York, 2002: 886-909.
23. Brondsted H, Andersen C, Hovgaard L. Crosslinked dextran - a new capsule material for colon targeting of drugs. J Control Release. 1998;53(1-3):7-13.
24. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991;32(1):50-54.
25. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 1992;103(1):65-71.
26. Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut. 1992;33(7):929-932.
27. Collier HO, Francis AA, McDonald-Gibson WJ, Saeed SA. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins. 1976;11(2):219-225.
28. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978; 75(4):638-640.
29. Nahor H, Chell N, Kamyar H, et al. A multi-scale stochastic drug release model for polymer-coated targeted drug delivery systems. J Control Release. 2006;110(2):314-322.
30. François L, Louis C, Roch T. New methods characterizing avalanche behavior to determine powder flow. Pharm Res. 2002;19(66):887-893.
31. nd Ed. Aulton, M.E., eds.; Churchill Livingstone: London, 2002, 197-210.
32. John S. Powder flow. In: Aulton ME, ed. Pharmaceutics: The Science of Dosage Form Design. 2nd ed.., London: Churchill Livingstone; 2002:197-210.
33. Markus R, Sandra K, Thomas B, Hans-Ulrich P, Jennifer D. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001;51(3):183-190.
34. Sangalli ME, Maroni A, Foppoli A, Zema L, Giordano F, Gazzaniga A. Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances. Eur J Pharm Sci. 2004;22(5):469-476.
35. Sawada T, Sako K, Fukui M, Yokohama S, Hayashi M. A new index, the core erosion ratio, of compression coated rimed release tablets predicts the bioavailability of acetaminophen. Int J Pharm. 2003;265(1-2):55-63.
36. Ahmed IS. Effect of simulated gastrointestinal conditions on drug release from pectin or ethyl cellulose as film coating for drug delivery to the colon. Drug Dev Ind Pharm. 2005;31(4-5):465-470.
37. British Pharmacopoeia, Appendix XII B. HMSO, London, 2001.
38. Qing RC, Han GC, Dong CK, Beom JL. Release behavior and photo image of nifedipine tablet coated with high viscosity grade hydroxypropyl methylcellulose: effect of coating conditions. Int J Pharm. 2004;274(1-2):107-117.
39. Goebell H, Klotz U, Nehlsen B, Layer P. Oroileal transit of slow release 5-aminosalicylic acid. Gut. 1993;34(5):669-675.
40. Layer PH, Goebell H, Keller J, Dignass A, Klotz U. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 1995;108(5):1427-1433.
41. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17(1):29-42.
42. Fatmanur TCDZ, Acartu FSR, Sevgi T, Konus OZ, Boyunag A. In-vitro and in-vivo evaluation of mesalazine-guar gum matrix tablets for colonic drug delivery. J Drug Targeting. 2004;12(2):105-112 .
43. Wirth DD, Baertschi SW, Johnson RA. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci. 1998;87(1):31-39.
44. Rowe RC, Sheskey PJ, Weller PJ, eds. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2003.
45. Banker GS, Anderson NR. Tablets. In: Lachman L, Liberman HA, Kanig JL, eds. The Theory and Practice of Industrial Pharmacy. Mumbai, India: Varghese Publishing House; 1987:293-345.
46. Martin A, ed. Physical Pharmacy: Physical Chemical Principles in Pharmaceutical Sciences. Baltimore, MD: Lippincott Williams & Wilkins; 2001.
47. Haeberlin B, Friend DR. Anatomy and physiology of the gastrointestinal tract: implications for colonic drug delivery. In: Friend, D.R., ed. Oral Colon-Specific Drug Delivery. Boca Raton, FL: CRC Press; 1992:1-44.
48. Ashord M, Fell JT, Attwood D, Woodhead PJ. An in vitro investigation into the suitability of pH dependent polymers for colon targeting. Int J Pharm. 1993;91(2-3):241-245.